Literature DB >> 7872052

Structural requirements for bisphosphonate actions in vitro.

E van Beek1, M Hoekstra, M van de Ruit, C Löwik, S Papapoulos.   

Abstract

We investigated the structural requirements for the binding of bisphosphonates to bone mineral and the relation between their affinity for bone and their effects on bone resorption in vitro. For this we used fetal mouse long bones in culture and bisphosphonates with variable R1 and R2 structures. In addition, we studied the effect of structural differences in the incorporation of calcium into bone. We found that bisphosphonates containing a hydroxyl group in the R1 position have the highest affinity for bone mineral. This was related to their capacity to inhibit the incorporation of calcium into long bones but not to their antiresorptive potency. The latter was primarily determined by R2. Furthermore, the effect of bisphosphonates on calcification, but not on resorption of bone explants, was mainly determined by the mode of addition. The continuous presence of bisphosphonate during culture inhibited calcification even at very low concentrations, but short incubation of the bones with relatively high concentrations had no effect. This is probably a result of differences in the availability of the compound to the process of calcification. Because, in vivo, the more potent bisphosphonates inhibit resorption without adversely affecting mineralization of the skeleton and they disappear rapidly from the circulation after administration, we suggest that cultures of bone explants incubated with bisphosphonates for short times rather than cultures in which the drugs are continuously present provide more accurate information about the in vivo effect of these compounds on both resorption and calcification.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7872052     DOI: 10.1002/jbmr.5650091206

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  25 in total

1.  Bisphosphonates and tetracycline: experimental models for their evaluation in calcium-related disorders.

Authors:  H Cohen; V Solomon; I S Alferiev; E Breuer; A Ornoy; N Patlas; N Eidelman; G Hägele; G Golomb
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

Review 2.  Bisphosphonate-based strategies for bone tissue engineering and orthopedic implants.

Authors:  Juan Pablo Cattalini; Aldo R Boccaccini; Silvia Lucangioli; Viviana Mouriño
Journal:  Tissue Eng Part B Rev       Date:  2012-05-14       Impact factor: 6.389

3.  Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1)-a novel bisphosphonate.

Authors:  H Cohen; I S Alferiev; J Mönkkönen; M J Seibel; T Pinto; A Ezra; V Solomon; D Stepensky; H Sagi; A Ornoy; N Patlas; G Hägele; A Hoffman; E Breuer; G Golomb
Journal:  Pharm Res       Date:  1999-09       Impact factor: 4.200

4.  Sustained beneficial effect of intravenous bisphosphonates after their discontinuation in children.

Authors:  Kim M Waterhouse; Ari Auron; Tarak Srivastava; Connie Haney; Uri S Alon
Journal:  Pediatr Nephrol       Date:  2006-10-11       Impact factor: 3.714

Review 5.  Utility of bisphosphonates in treating bone metastases.

Authors:  G Merlini; I Turesson
Journal:  Med Oncol       Date:  1996-12       Impact factor: 3.064

6.  Pharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders.

Authors:  Luigi Sinigaglia; Massimo Varenna; Silvia Casari
Journal:  Clin Cases Miner Bone Metab       Date:  2007-01

Review 7.  Bisphosphonates in bone diseases.

Authors:  R W Sparidans; I M Twiss; S Talbot
Journal:  Pharm World Sci       Date:  1998-10

Review 8.  Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents.

Authors:  Hideki Hirabayashi; Jiro Fujisaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 9.  Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.

Authors:  Frieder Bauss; R Graham G Russell
Journal:  Osteoporos Int       Date:  2004-03-26       Impact factor: 4.507

10.  Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.

Authors:  J E Fisher; M J Rogers; J M Halasy; S P Luckman; D E Hughes; P J Masarachia; G Wesolowski; R G Russell; G A Rodan; A A Reszka
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.